AmethIntel™ · Services & Collaborations
Grant narratives, investor decks, and partnering packages built to survive diligence.
You have the science. What's missing isn't the idea — it's the translation.
Service Levels
AmethIntel™ packages healthtech and biotech projects at four levels, each building on the last.
Turn the science into a grant application, investor deck, or pharma-ready dossier that reads like it came from inside the industry, not academia.
Patent, publication, and product analysis to surface the USPs that will actually hold up under diligence — and survive a crowded field.
Competitive landscape, market sizing, and a defensible valuation — the case you'd need to walk into a partnering meeting and not blink.
External marketing partner handling LinkedIn, Substack, and biotech media presence, plus focused, targeted outreach to the partners who should already know you exist.
Proof, Not Promises
Our CEACAM5 report mapped 187 clinical trials and 44 competitor products and platforms to chart a ten-year leadership path in a target already covered by a 6,000-patent estate.
That's L2/L3 rigor. The same discipline scales down to a 20-page SBIR narrative or a 10-slide partnering deck — and L4 makes sure the right people see it.
Read the CEACAM5 reportWhy Us
25 years in pharma/biotech BD; PhD in human pathology (Saint Louis University), MBA (Olin School of Business); deal structuring, KOL architecture, and FTO analysis across the US, Canada, Australia, Europe, and India. Track record includes American Heart Association (MidWest Chapter) grants and fellowships, an Indo-Australian grant, and funded business plans for three biotech companies across the US, Canada, and Australia.
PhD (Saint Louis University), NCI postdoctoral fellow; career built in high-end diagnostics and RUO sales and marketing, with a proteomics focus.
PhD (Saint Louis University), postdoc (Washington University); BD lead on licensing diabetes, oncology, and NSAID assets; project management and market research; has raised Indo-Australian funding for clients.
How We Work With Partners
What we claim, how we manage exclusivity, and what value optimization means in practice. Select a pillar to read our approach.
Choose a pillar above to see how we work.
In the age of generative AI, we still work the old-fashioned way: every claim carries a reference — a peer-reviewed citation or a patent number. Where the information doesn't exist, we say so and flag it as a gap. Nothing is generated to fill a page.
AmethIntel™ agrees the scope of exclusivity with each partner up front. We do not take on two assignments that overlap or conflict — full stop. Existing clients are kept informed, at a portfolio level, of where else we're active, without compromising anyone's confidentiality. The field is large enough that our entire roster of partnerships is a small fraction of it — we'd rather have happy partners than the overlap it would take to squeeze out more.
The tools aren't new — patent analysis and literature review are standard practice. What's different is the objective: we run these searches to increase the value of a client's project, not simply to document prior art.